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Bioresorbable and bioactive tissue engineering scaffolds based on bioactive glass (45S5 Bioglass®) particles and 
macroporous poly(DL-lactide) (PDLLA) foams were fabricated. A slurry dipping technique in conjunction with 
pretreatment in ethanol was used to achieve reproducible and well adhering bioactive glass coatings of uniform 
thickness on the internal and external surfaces of the foams. In vitro studies in simulated body fluid (SBF) 
demonstrated rapid hydroxyapatite (HA) formation on the surface of the composites, indicating their bioactivity. 
For comparison, composite foams containing Bioglass® particles as filler for the polymer matrix (in 
concentration of up to 40 wt%) were prepared by freeze-drying, enabling homogenous glass particle distribution 
in the polymer matrix. The formation of HA on the composite surfaces after immersion in phosphate buffer 
saline (PBS) was investigated to confirm the bioactivity of the composites. Human osteoblasts (HOBs) were 
seeded onto as-fabricated PDLLA foams and onto PDLLA foams coated with Bioglass® particles to determine 
early cell attachment and spreading. Cells were observed to attach and spread on all surfaces after the first 90 
min in culture. The results of this study indicate that the fabricated composite materials have potential as 





In recent years, composite materials have gained increasing importance in the biomedical field because, unlike 
with monolithic materials, flexible tailoring of their properties can be accomplished, hence the materials show 
better adaptation to the complex environment and demands of the human body. Recent complete review articles 
covering the multitude of medical and clinical applications of composite materials have been published by 
Thompson and Hench [1] and Ramakrishna et al. [2]. A great deal of research in the biomedical field concerns 
the investigation of alternatives to the current practice of replacing damaged or diseased tissues with permanent 
implants due to problems related to the long-term performance of such implants [3]. One promising alternative is 
"tisue engineering" which combines engineering principles with the life sciences to enable the regeneration of 
tissues by exploiting the body's inherent  repair  mechanisms   [4]. Tissue engineering requires a suitable 
temporary scaffold or regenerative allograft which, for bone tissue engineering, must fulfil a set of complex 
criteria as shown in Table I [5]. 
A wide variety of bioresorbable materials have been investigated as scaffolds for tissue engineering applications, 
including natural [6,7] and synthetic polymers [8-12]. Synthetic polymers have the advantage to enable precise 
engineering of macro- and microstructure and control of material composition so that optimal conditions for cell 
survival, proliferation, and subsequent tissue formation can be created [8]. 
Synthetic bioresorbable polymers, in particular polylactic acid (PLA), polyglycolic acid (PGA) and their 
copolymers, are successful candidates as scaffold materials [12]. They are currently used in clinics, for example, 
as resorbable surgical sutures and meshes or as drug delivery systems. A major drawback of these materials, 
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TABLE I   Criteria for an ideal scaffold for bone tissue engineering 
 
An ideal tissue engineering scaffold 
1. is made from a material that is biocompatible, i.e. not cytotoxic; 
2. acts as template for tissue growth in three dimensions; 
3. has an interconnected macro-porous network for vascularization, tissue ingrowth and nutrient delivery; 
4. bonds to the host tissue without the formation of scar tissue; 
5. influences the genes in the bone generating cells to enable efficient cell differentiation and proliferation; 
6. resorbs at the same rate as the tissue is repaired, with degradation products that are non-toxic and that can be easily 
excreted by the body, for example via the respiratory or urinary systems; 
7. is made from a processing technique that can produce irregular shapes to match that of the defect in the bone of the 
patient; and 
8. exhibits mechanical properties sufficient to be able to regenerate bone in load bearing sites. 
 
Another limitation is their lack of bioactivity, which means, for the case of bone tissue engineering, that they do 
not allow bone apposition or bonding on the polymer surface [14]. 
Certain ceramic materials, such as hydroxyapatite (HA), tricalcium phosphate (TCP) and selected compositions 
of silicate and phosphate glasses, and glass-ceramics, for example, the commercially available Bioglass®, react 
with physiological fluids and form tenacious bonds to bone tissue through cellular activity. These materials are 
therefore known as "bioactive" [15]. 
Biodegradability and bioactivity can be combined in the form of composite materials to obtain optimized tissue 
engineering scaffolds exhibiting tailored physical and mechanical properties and controllable resorption rates in 
the body [16,17]. Bioresorbable and bioactive composites are being developed worldwide, most commonly using 
combinations of polylactide (PLA), polyglycolide (PGA) and other resorbable polymers, and HA, TCP or 
bioactive glasses and glass-ceramics in different scaffold architectures [16-25]. The most usual approaches 
involve HA, TCP, and bioactive glas particles or fibers used either as fillers or in the form of coatings in porous 
polymeric biodegradable substrates, as reviewed elsewhere [16]. 
In the present work bioactive and bioresorbable composite materials were fabricated using macroporous 
poly(DL-lactide) (PDLLA) foams coated with and impregnated by bioactive glass (Bioglass®) particles 
following a previously developed technique [26]. The in vitro response of the composites in contact with 
simulated body fluid (SBF) was assessed. For comparison, the in vitro behavior in phosphate buffer saline (PBS) 
of composites made using Bioglass® particles as filler in PDLLA foams was also investigated. Cell culture 
studies with human osteoblasts (HOB's) were carried out to assess cell attachment and proliferation on 
Bioglass®-coated scaffolds. The present work complements recent research on the use of Bioglass® as the 





2.1. Materials and processing 
 
Poly(DL-lactide) (PDLLA) foams were fabricated by a thermally induced phase separation process, often termed 
freeze-drying, which has been described in detail elsewhere [11a,b]. Briefly, 2 g of PDLLA (Purasorb®; Purac 
biochem, Holland), with inherent viscosity of 1.52 dl/g, were dissolved in 40 ml of dimethylcarbonate (99%, 
Acros) under magnetic stirring overnight. The solution was then transferred into a 150 ml lyophilization flask 
and frozen for 2h by quenching in liquid nitrogen. The flask was connected to a vacuum pump (10 -2 Torr), and 
the solvent was sublimated at - 10 °C for the first 48 h, followed by an additional 48 h at 0 °C. The residual 
solvent was removed at ambient temperature until the foam reached a constant weight. In a separate experiment, 
the freeze-drying process was conveniently modified for the incorporation of bioactive glass particles in different 
concentrations (5-40 wt %) into the PDLLA matrix, as described elsewhere [29]. 
The bioactive material used was a melt-derived bioactive glass powder (Bioglass® grade 45S5, US Biomaterials 
Co., Alachua, FL, USA). The powder had a mean particle size < 5 µm. The composition of the bioactive glass 
was (in weight percentage): 45% SiO2, 24.5% Na2O, 24.5% CaO, and 6% P2O5, which is the original bioactive 
glass composition developed by Hench and coworkers [15]. 
A slurry-dipping technique, which has been described in detail elsewhere [26], was used to coat and infiltrate 
PDLLA foams with Bioglass® particles. The technique involved the preparation of a stable slurry with 42 wt % 
of Bioglass® particles in distilled and deionized water. The foams were pretreated in ethanol for 12 h following a 
procedure described by Mikos et al. [30], in order to decrease the hydrophobicity of the foam thus improving 
infiltration of the glass particles into the pores and enhancing coating homogeneity. Immersion time in the 
Bioglass® slurry was 5 min. After withdrawal from the slurry, the samples were slowly dried on glass plates at 
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ambient temperature in humid atmosphere. 
 
2.2. Characterization and in vitro studies 
 
For material characterization with scanning electron microscopy (SEM), the samples were cut with a razor blade 
to enable analysis of longitudinal and transverse cross sections. The coating quality and degree of infiltration was 
assessed on gold-plated samples using an accelerating voltage of 20-25 kV. 
In vitro studies in simulated body fluid (SBF) [31] were performed using Bioglass®-coated and uncoated PDLLA 
foams. The samples were immersed in 75 ml of SBF in clean conical flasks, which had been washed using 
hydrochloric acid and deionized water. The conical flasks were then placed in an orbital shaker (New Brunswick 
Scientific, C24 Incubator Shaker), which rotated at 175 rpm at a controled temperature of 37 °C. 
The PDLLA /Bioglass® foams and uncoated PDLLA foams were left in immersion in SBF for time periods of 7, 
14, 21, and 28 days. SBF was changed every seven days as cation concentration decreased during the course of 
in vitro studies, as a result of the changes in the chemistry of the materials, as discussed below. After immersion 
in SBF, the samples were characterized using SEM. Raman spectroscopy was used to verify whether HA 
formation had occurred on the surfaces of selected samples. For comparison, Bioglass®-filled composite foams 
(non-coated) were immersed in phosphate buffer saline (PBS) for up to 16 weeks to assess their bioactivity. The 
crystallinity of HA formed on the surface of these composites was investigated by X-ray diffraction (XRD). 
 
2.3. Human osteoblast cell culture 
 
Sterilization of the Bioglass®-coated and as-received foams was carried out using UV light source in a tissue 
culture laminar flow hood for 20 min on each side. 
Primary human osteoblasts were isolated as described in the literature [32, 33]. Trabecular bone from femoral 
heads obtained after hip replacement surgery was cut into fragments of approximately 3 mm x 3 mm. Fragments 
were washed several times in phosphate buffered saline (PBS) to remove blood cells and debris with a final wash 
in culture medium. Fragments were then placed into culture flasks in complete Dulbecco's Modified Eagle 
Medium (DMEM) containing 10% Foetal Bovine Serum (FBS) with 1% glutamine, 2% penicillin/streptomycin, 
and 200 µM L-ascorbic acid 2-phosphate. The fragments were incubated at 37 °C in a humidified incubator with 
5% CO2. After culture for 7-10 days, fragments were subjected to trypsin (0.02%) and collagenase (0.162 U/ ml) 
digestion for 20 min at 37 °C on a roller mixer. The resulting HOB cell suspension was then centrifuged at 1000 
rpm and enzyme digestion of the fragments repeated. The digestion was performed five times in total and cells 
pooled. HOBs were cultured as described above on material samples or Thermanox® and Bioglass®) discs as 
positive controls, for 30, 60, and 90 min, and 4h, at a density of 40 000 cells/cm2. Cells were tested for the 
osteoblastic phenotype using an alkaline phosphatase assay and their ability to mineralize in culture (data not 
shown). 
After culture for various time periods, the samples were washed twice in PBS and fixed in 4% paraformaldehyde 
for 10 min at room temperature. The samples were then washed in PBS and permeabilized in 0.2% Triton for 5 
min at -20°C. This was followed by washing in PBS containing 1% bovine serum albumin (PBS/BSA). Samples 
were stained using Alexa Fluor 488 phalloidin (Molecular Probes) at a concentration of 40 U/ ml (according to 
manufacturers recommendations) for 20 min at room temperature. Samples were then counterstained with 
propidium iodide at a concentration of 5 µg/ ml in PBS for 30 s at room temperature. 
The samples were washed several times, placed onto glass slides and mounted under coverslips using PBS/ 
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3.1.  Materials characterization 
 
The typical morphology of PDLLA foams prepared by freeze-drying is shown in Fig. 1. The foam exhibits two 
distinct pores sizes, i.e. macropores of > 100 µm average diameter and interconnected micropores with an 
average diameter of 20-30 µm. The tubular macropores are highly oriented as a result of the unidirectional 
cooling process. PDLLA foams coated by Bioglass® particles were fabricated using a slurry-dipping technique. 
Fig. 2(a,b) shows SEM micrographs of Bioglass®-coated PDLLA foams at different magnifications. No peel-off 
of Bioglass® particles or macrodelamination of the Bioglass® coating were observed. It could be observed that 
the material exhibited a thin, even film of Bioglass® that covered the surfaces of the foam. Using an immersion 
time of 5 min, Bioglass® particles deeply infiltrated the pores of the material and glass particles were deposited 
evenly along the internal surfaces of the porous structure. Due to the slow drying process used, the occurrence of 
microcracks was eliminated. 
 
3.2.  In vitro studies in SBF 
 
The response of Bioglass®-coated foams in contact with SBF was analyzed qualitatively using SEM and Raman 
spectroscopy. Fig. 3(a) shows the development of HA crystals on the surface of the foam after 7 days in SBF. In 
Fig. 3(b) it is shown that complete covering of the surface with HA has occurred after 28 days in SBF. The 
formation of HA on the surface of the coated PDLLA foam samples with increasing days of immersion in SBF 
was confirmed by Raman spectroscopy. Fig. 4 presents the Raman spectra of Bioglass®-coated foams after 
having been soaked in SBF for 7 days. For comparison, the spectrum for a sample in the as-fabricated condition 
is also shown. The formation of the hydroxyapatite layer on the surface of the Bioglass®-coated PDLLA foam is 
indicated by the strong peak at 964 cm-1, which corresponds to the symmetric stretching vibration of P-O in 
PO4
3- tetrahedra belonging to hydroxyapatite crystals [34,35]. For similar composite samples, the crystallinity of 
the HA structure formed on the surface of the foams has been also confirmed by XRD [26]. The 875 cm-1 peak 
in the Raman spectra (Fig. 4) corresponds to C-COO stretching in PDLLA [36], therefore the ratio between the 
heights of the peaks at different immersion times may be used to quantify the relative amount of HA formed 
during immersion in SBF. 
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Figure 2 SEM micrographs showing the microstructure of Bioglass
®
-coated PDLLA foams produced by slurry-
dipping. The efficient infiltration of Bioglass
®
 particles into the pores (a) and the homogeneous coating 
microstructure (b) can be observed. 
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Figure 3 SEM micrographs showing surfaces of Bioglass
®
-coated PDLLA foams after degradation in contact 
with SBF for: (a) 7 days and (b) 28 days. The micrographs reveal formation of HA crystals and development of a 
surface HA layer. 
 
The qualitative in vitro studies in SBF were successful in confirming the high ability for hydroxyapatite (HA) 
formation on the Bioglass®-coated foam surfaces, which is a measure of the considerable biaoctivity of the 
materials. It was also confirmed that the structure and morphology of the HA layer changed during immersion in 
SBF. Small HA crystals deposited after the first week of immersion, which developed into a continuous HA 
layer formed by coalescence of large crystals after the third week of immersion in SBF (see Fig. 3(a),(b)). 
The results of the in vitro behavior of Bioglass®-filled foams after immersion in PBS are similar in that rapid 
formation of HA crystals on the samples' surfaces was found. Fig. 5 shows XRD diagrams of PDLLA/ Bioglass® 
composite samples containing 40 wt % Bioglass®. Results for samples incubated for 7 and 28 days in PBS are 
shown. Well-defined HA peaks can be seen, which indicate the high bioactivity of the samples. A more detailed 
study of the in vitro behavior of samples containing different wt % of Bioglass® particles has been presented 
elsewhere [29]. 
 
3.3. Cell attachment study 
 
Early attachment of HOBs was tested on the four material surfaces with the Thermanox® and Bioglass® discs 
used as controls as shown in Fig. 6. It can be seen that for Thermanox® discs attachment and spreading was 
observed at the earliest time point studied (Fig. 6(a)). This is due to the fact that the material is an ideal substrate 
for cell attachment [33]. 
 
TABLE II   Summary of cell spreading of osteoblasts cultured on the material surfaces 
 
Material/time 30 min 90 min 4 h 
Thermanox® Cell attachment, cells beginning 
to spread 
More spreading with parallel stress 
fiber formation 
More spreading and more 
stress fiber formation 
Bioglass® disc Attachment and early spreading More spreading, cells appear spiky More spreading with 
parallel stress fiber 
formation 
PDLLA Foam Attachment and early spreading More spreading Cells become polarized 
with parallel stress fibers 
Bioglass®-coated 
PDLLA Foam 
Attachment with little spreading More cell spreading More cell spreading 
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After 90 min and 4 h, spreading increases further, and the formation of parallel stress fibers has occurred (Fig. 
6(b),(c)). Cell attachment and spreading occurs more slowly on Bioglass® discs. After 30 min, some spreading is 
observed although to a lesser extent than with Thermanox® discs (Fig. 6(d)). After 4 h in the cell culture similar 
developments of the cytoskeleton to those on Thermanox® discs are detected. The formation of a spiky 
cytoskeleton is evident, which is a typical feature observed for cell attachment on materials with rough surfaces, 
as demonstrated by Kieswetter et al. [37] and by Anselme et al. [38]. The Bioglass® discs in this study have a 3 
µm finish and are not as flat as the Thermanox® control. Attachment and spreading on the uncoated PDLLA 
foams is shown with stress fiber formation observed at 4 h, along with a highly polarized morphology, which is 




Figure 4 Raman spectra of Bioglass
®
-coated PDLLA foams (a) before and (b) after 7 days immersion in SBF, 




Figure 5 XRD pattern of Bioglass
®
-filled PDLLA foam composites (40 wt % Bioglass
®
 content) after immersion 
in PBS for 7 (a) and 28 (b) days, showing development of HA crystals. Note that the intensity is given in 
arbitrary units, i.e. the relative height of the peaks does not correlate with the relative amount of HA present in 
the different samples. 
 
Attachment and spreading of cells on the Bioglass®-coated PDLLA foams occurs at a slower rate than 
Thermanox® and Bioglass® disc controls and cells appeared less polarized than compared to cells on the 





The development of PDLLA/Bioglass® composite materials for bone tissue engineering applications is 
interesting due to the fact that PDLLA degrades in vitro without generation of any crystalline remnants. 
Heideman et al. have proved recently the complete resorption of PDLLA implants from the extracellular space in 
animal studies, hence confirming their tissue tolerance [39]. The course of degradation is more questionable for 
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slowly degradable, crystalline PLLA of high molecular weight. In some cases, degradation products are formed, 
including numerous stable and highly crystalline particles, which are responsible for a delayed inflammation and 
foreign body reactions at the site of implantation [40]. 
In the case of polymer/Bioglass® foams, the bioactive glass particles, applied as a coating of the pore walls, 
should act as a protective hydrolysis barrier affecting both the extent and rate of degradation of the polymer 
substrate, as suggested in recent investigations [27,28]. The rapid exchange of protons in water for alkali in the 
glass should provide a pH buffering effect at the polymer surface, therefore acceleration of degradation will not 
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Figure 6 Confocal laser scanning micrographs of primary human osteoblasts cultured on Thermanox
®
 discs for 
30min (a), 90min (b) and 4h (c), Bioglass
®
 discs for 30 min (d), 90 min (e) and 4h (f), PDLLA foams for 30 min 
(g), 90 min (h) and 4h (i) and Bioglass
®
-coated PDLLA foam for 30 min (j), 90 min (k) and 4h (l). Cells were 
stained with FITC-conjugated phalloidin for the actin cytoskeleton and counterstained with propidium iodide. 
 
The rapid formation of an HA layer on the Bioglass®-coated and filled PDLLA foams, both after immersion in 
SBF and PBS, indicates the high bioactivity of the materials. In particular for the Bioglass®-coated samples, it 
was found that the thickness of the HA layer increased with increasing time in solution and it was in all cases 
thicker than that formed on composites made using HA particles as bioactive phase [20]. After 21 days in SBF, 
for example, the HA layer had a thickness of ~ 10 µm, as determined by SEM examination of sample cross 
sections, as shown elsewhere [26]. It is well known that Bioglass® has a higher index of bioactivity than HA, 
which makes this material more suitable for applications in bone reconstruction [15]. It has been shown, for 
example, that there is much more bone formed in one week in the presence of Bioglass® than is formed when HA 
or other calcium phosphate ceramic particulates are placed in the same type of defect [41]. Recent investigations 
have shown also that there is genetic control of the cellular response of osteoblasts to bioactive glasses [3,41]. 
Moreover, since Bioglass® is a class A bioactive material (as opposed to HA, which is class B) it has shown a 
strong bond also to soft tissues [15]. The application potential of the Bioglass® containing composites fabricated 
could therefore encompass both hard and soft tissue regeneration and repair. 
Comparing the in vitro results of Bioglass®-coated and filled (40 wt % Bioglass® content) composites, one can 
conclude that both types of composites exhibit high bioactivity, both after immersion in SBF and PBS. A further 
investigation of the effect of Bioglass® weight content on bioactivity of similar PDLLA composite foams is 
being carried out. 
Osteoblast adhesion is an essential parameter when investigating bone-biomaterial interactions, since the 
development of bone-implant interfaces depends on the direct interactions of bone matrix and osteoblasts with 
the biomaterial [33,37,38]. Cell attachment and spreading was observed on all the surfaces tested, although 
spreading and stress fiber formation was slowest on the PDLLA foams and Bioglass® coated foams. This may 
not impede the long term phenotype of the cells as in vivo osteoblasts are cubiodal rather than spread and 
flattened as seen on Thermanox® or tissue culture plastic controls. Further investigation is necessary in order to 
make a clear statement on the cell behavior on the materials, particularly to assess the effect of the Bioglass® 
coating. Experiments are underway analysing cell infiltration into the porous network and expression of the long 





Bioactive and bioresorbable composites were developed based on three dimensional, macroporous poly(D,L)-
lactic acid (PDLLA) foams, and Bioglass® particles. A cost-effective processing technique, slurry-dipping, led to 
stable and uniform glass coatings as well as adequate infiltration of Bioglass® particles into the porous network 
of the foams. Bioglass®-coated foams developed a surface HA layer after 7 days immersion in SBF. Bioglass®-
filled PDLLA foams were also assessed for their in vitro behavior using PBS. HA formation, and therefore 
bioactive behavior, was detected in composites containing 40 wt % Bioglass® after 7 days in PBS. Initial 
osteoblast attachment shows progressive spreading on both uncoated PDLLA foams and Bioglas®-coated 
PDLLA foams. Further investigations are underway analyzing proliferation, osteoblast phenotype and cell 
infiltration into the porous network. The results available so far indicate that the fabricated PDLLA/Bioglass® 
foams, with their tailored, oriented porosity, high bioactivity, and favorable cell response are attractive scaffolds 
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